UNIVERSITAS
GADJAH MADA

Perbedaan Nilai Rasio Vascular Endothelial Growth Factor/Endostatin Serum Pada Pasien Kanker Payudara Metastasis dan Non-Metastasis
Swastika Dewi , dr. Andaru D., M.Kes, Sp.PK(K) & dr. Osman S., DMM, MSc, Sp.PK(K)
Universitas Gadjah Mada, 2012 | Diunduh dari http://etd.repository.ugm.ac.id/

PERPUSTAKAAN
FK.UGM

DAFTAR PUSTAKA

Alshenawy, H.A., 2010. *Prognostic significance of vascular endothelial growth factor, basic fibroblastic growth factor, and microvessel density and their relation to cell proliferation in B-cell non-Hodgkin's lymphoma.* Tanta University, Egypt.

American Joint Committee on Cancer, 2010, Breast Cancer Staging, 7th edition.

Aryandono, T., 2006. *Faktor Prognosis Kanker Payudara Operabel di Yogyakarta* (Desertasi untuk memperoleh Derajat Doktor dalam Ilmu Kesehatan). Universitas Gadjah Mada, Yogyakarta.

Benoy, I., Salgado, R., Colpaert, C., Weytjens, R., Vermeulen, P.B., Dirix, L.Y., 2002. Serum Interleukin 6, Plasma VEGF, Serum VEGF, and VEGF Platelet Load in Breast Cancer Patients. *Clinical Breast Cancer* 4(2):311-315.

Boehm, T., Folkman, J., Browder, T., O'Reilly, M.S. 1997., Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance, *Nature* 390:404-407.

Chernecky, C.C., Berger, B.J., 2008, *Laboratory Tests and Diagnostic Procedures*. 5th ed., Saunders Elsevier, Missouri.

Copeland, E.M., Bland, K.I., 1992. *Payudara : Sabiston, D.C. (ed). Essential of Surgery. Edisi pertama* (Alih bahasa oleh Andrianto, P., Timan, I.S., Oswari, J.) EGC, Jakarta.

Coskun, U., Gunel, N., Toruner, F.B., Sancak, B., Onuk, E., Bayram, O., et. al., 2003. Serum leptin, prolactin and vascular endothelial growth factor (VEGF) levels in patients with breast cancer. *Neoplasma* 50:41-46.

Demirkazik, A., Akbulut, H., Ulger, F., Arican, A., Ozer, I., Acikgoz, N., Icli, F., 2004. Serum vascular endothelial growth factor levels in patients with non-samall cell lung cancer. *Annals of Saudi Medicine* 24(5):473-475.

DiSaia, P.J., Creasman, W.T., 1997. *Clinical Gynecologic Oncology* 5th ed. Mosby-Year Book, Missouri.

Dixelius, J., Cross, M., Matsumoto, T., Sasaki, T., Timpl, R., Claesson-Welsh, L., 2002, Endostatin regulates endothelial cell adhesion and cytoskeletal organization. *Cancer Research* 62:1944-1947.

UNIVERSITAS
GADJAH MADA
Perbedaan Nilai Rasio Vascular Endothelial Growth Factor/Endostatin Serum Pada Pasien Kanker Payudara Metastasis dan Non-Metastasis
Swastika Dewi , dr. Andaru D., M.Kes, Sp.PK(K) & dr. Osman S., DMM, MSc, Sp.PK(K)
Universitas Gadjah Mada, 2012 | Diunduh dari http://etd.repository.ugm.ac.id/

Donegan, W.L., 1997. Tumor-related Prognostic Factors for Breast Cancer. *CA Cancer J. Clin;* 47:28-51.

Dvorak, H.F., Brown,L.F., Detmar,M., and Dvorak,A.M., 1995. Vascular Permeability Factor/Vascular Endothelial Growth Factor, Microvascular Hyperpermeability and Angiogenesis. *Am JP* 146:1029-39.

Edel, M.J., Harvey, J.M., Papadimitriou, J.M., 2001. Comparison of vascularity and angiogenesis in primary invasive mammary carcinomas and in their respective axillary lymph node metastases. *Clinical and Experimental Metastasis* 18: 695-702.

Fauci, A.S., Kasper, D.L., Longo, D.L., Braunwald, E., Hauser, S.L., Jameson, J.L., Loscalzo, J., 2008. *Harrisson's Principles of Internal Medicine.* McGraw-Hill, New York.

Feldman, A.L., Tamarkin, L., Paciotti, G.F., et. al., 2000. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patient with stage IV clear cell renal cancer. *Clinical Cancer Research* 6:4628-4634.

Ferrara, N., Gerber, H.P., LeCouter, J. 2003. The biology of VEGF and its receptors. *Nature Medicine* 9:669-76.

Fidler, I.J., Kerbel, R.S., Ellis, L.M. 1993. Biology of Cancer: Angiogenesis. In: DeVita, V.T.Jr., Hellman, S., Rosenberg, S.A. (Ed): *Cancer, Principles & Practice of Oncology,* 6th ed. Lippincott Williams & Wilkins, Philadelphia.

Folkman, J., 1995. Clinical applications of research on angiogenesis. *NEJM* 333: 1757-63.

Fukumoto, S., Morifuji, M., Katakura, Y., Ohishi, M., Nakamura, S. 2005. Endostatin inhibits lymph node metastasis by a down-regulation of the Vascular endothelial growth factor C expression in tumor cells. *Clinical & Experimental Metastasis* 22:31-38.

Gasparini, G. 2000. Prognostic value of vascular endothelial growth factor in breast cancer. *Oncologist* 5: 37-44.

Hanai, J.I., 2002. Endostatin is a potential inhibitor of Wnt signaling, *Journal of Cell Biology* 158:529.

Heer, K., Kumar, H., Speirs, V., Greenman, J., Drew, P.J., Fox, J.N., Carleton, P.J., Monson, J.R.T., Kerin, M.J., 1998. Vascular endothelial growth factor in premenopausal women - indicator of the best time for breast cancer surgery?. *British Journal of Cancer* 78(9):1203-1207.

UNIVERSITAS
GADJAH MADA
Perbedaan Nilai Rasio Vascular Endothelial Growth Factor/Endostatin Serum Pada Pasien Kanker Payudara Metastasis dan Non-Metastasis
Swastika Dewi , dr. Andaru D., M.Kes, Sp.PK(K) & dr. Osman S., DMM, MSc, Sp.PK(K)
Universitas Gadjah Mada, 2012 | Diunduh dari http://etd.repository.ugm.ac.id/

Heryanto, Y.D., 2004. Hubungan Infiltrasi Tumor Associated Macrophages (TAMs) dan Ekspresi Vascular Endothelial Growth Factor (VEGF) Dengan Derajat Histologi dan Stadium Karsinoma Payudara. Universitas Gadjah Mada, Yogyakarta.

Jardines, L., Goyal, S., Fisher, P., Weitzel, J., Royce, M., 2009. Breast Cancer Overview: Risk Factors, Screening, Genetic Testing, and Prevention. In: Pazdur, R., Wagman, L.D., Camphausen, K.A., Hoskins, W.J. (Ed): *Cancer Management: A Multidisciplinary Approach* 12th ed. CMP Media.

Jardines, L., Haffty, B.G., Doroshow, J.H., Fisher, P., Weitzel, J., Theriault, R.L., 2005. Breast Cancer Overview: Risk Factors, Screening, Genetic Testing and Prevention.

Jemal, A., Bray, F., Center, M.M., et al., 2011. Global Cancer Statistic. *CA Cancer J Clin*, Feb 4 (Epub ahead of print)

Katsios, C., Ziogas, D.E., Roukos, D.H., 2011. New Molecular Oncology-changing Era: Prospects and Challenges of Cancer Genome and Integrative Systems Biology. Expert Review. *Anticancer Therapy*. 11:5-8.

Kumar, V., Abbas, A.K., Fausto, N., 1999. Robbins and Cotran Pathology Basis of Disease, 7th ed. Elsevier, Philadelphia.

Kuroi, K., Tanaka, C., Toi, M., 2001. Circulating levels of endostatin in cancer patients, *Oncology Reports* 8:405-9.

Liotta, L.A., 1985. Mechanisms of cancer Invasion and Metastasis, Important Advances in Onkology. J.B. Lipppincott Company, Philadelphia.

Minchenko, A., Bauer, T., Salceda, S., Caro, J., 1994. Hypoxiastimulation of vascular endothelial growth factor expressionin vitro and in vivo. *Laboratory Investigation* 71:374-379.

Neufeld, G., Cohen, T., Gengrinovitch, S., Poltorak, Z., 1999. Vascular endothelial growth factor (VEGF) and its receptors. *FASEB*, 13:9-22.

O'Reilly, M.S, Boehm, T., Shing, Y., et. al., 1997. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. *Cell* 88:277-85.

Raharja, E.S.P., 2006. Hubungan Antara Ekspresi Vascular Endothelial Growth Factor (VEGF) Dengan Stadium Dan Derajat Histologis Karsinoma Payudara. Universitas Gadjah Mada, Yogyakarta.

Rajkumar, T., 2010. Personalised Medicine:FAQs. *Indian Journal of Medical & Paediatric Oncology* 31:72-74.

UNIVERSITAS
GADJAH MADA
Perbedaan Nilai Rasio Vascular Endothelial Growth Factor/Endostatin Serum Pada Pasien Kanker Payudara Metastasis dan Non-Metastasis
Swastika Dewi , dr. Andaru D., M.Kes, Sp.PK(K) & dr. Osman S., DMM, MSc, Sp.PK(K)
Universitas Gadjah Mada, 2012 | Diunduh dari http://etd.repository.ugm.ac.id/

Ramli, H.M., Zafiral, A.A, Tjindarbumi, D., Lukitto, P., Reksoprawiro, S., 2004. Protokol PERABOI 2003, I Ed. Perhimpunan Ahli Onkologi Indonesia, Jakarta.

Ruddon, R.W., 2007. The Biochemistry and Cell Biology of Cancer. In: Raymound WR (Ed): *Cancer Biology* 4th ed, pp: 117-256. Oxford University Press.

Saika, K., Sobue, T., 2009. Epidemiology of Breast Cancer in Japan and the US. *Japan Medical Association Journal* 52(1):39-44.

Shweiki, D., Neeman, M., Itin, A., et. al., 1995. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis. *PNAS* 92:768-72.

Singletary, S.E., Alfred, C., Asley, P., Basset, L.W., Berry, D., Bland, K.I., Booergen, P.I., Clark, G., Edges, S.B., Hayes, D.F., Hughes, L.L., Hutter, R.V.P., Morrow, M., Page, D.L., Rect, A., Theriault, R.L., Thor, A., Weaver, D.L., Wieand, H.S., Greence, F.L., 2002. Revision of the American Joint Commite on Cancer Staging System for Breast Cancer, *Journal of Clinical Oncology* 20:3628-3636.

Thickett, D.R., Armstrong, L., Millar, A.B., 1999. Vascular Endothelial Growth Factor (VEGF) in Inflamatory and Malignant Pleural Effusions. *Thorax* 54:707-10.

Van de Velde, C.J.H., Bosman, F.T., Wagener, D.J.Th., 1996. *Onkologi*. Panitia Kanker RSUP Dr. Sardjito, Yogyakarta.

Venes, D., et.al., 2005. *Taber's Cyclopedic Medical Dictionary*. F.A. Davis Company. Philadelphia.

Wickstrom, S.A., Alitalo, K., Keski, O.J., 2005. Endostatin signaling and regulation of endothelial cell-matrix interactions. *Advances in Cancer Research* 94:197-229.

Yamaguchi, N., Anand-Apte, B., Lee, M., Sasaki, T., Fukai, N., Shapiro, R.,Que, I., Lowik, C., Timpl, R., Olsen, B.R., 1999. Endostatin inhibits VEGF induced endothelial cell migration and tumor growth independently of zinc binding. *The EMBO Journal* 18(16):4414-4423.

Zhao, J., Feng, Y., Huangxian, J., Jinhai ,T., Jianwei, Q., 2004. Correlation between serum vascular endothelial growth factor and *endostatin* levels in patients with breast cancer *Cancer Letters* 204:87-95.